rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    DRTS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Alpha Tau Medical: The Rubber Meets The Road In H1 2027
      6h agoSeeking AlphaDRTS
      Alpha Dart Therapy Shows Complete Tumor Clearance in Five Brain Cancer Patients
      Nov 16BenzingaDRTS
      12 Health Care Stocks Moving In Monday's Pre-Market Session
      Nov 16BenzingaAKANDRTS
      Alpha Tau Announces New Positive Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial: All Patients Treated are Alive with Median Survival Not Reached, 6.9 Months Median Follow-Up in the First Six Evaluable Patients With 100% ORR, 100% Feasibility and No Unanticipated Serious Adverse Events - Conference Call Scheduled for 8:30am ET November 16

      - All eight treated brain cancer patients in the trial remain alive as of November 11, 2026; median overall survival has not been reached, with a median follow-up of 6.9 months from trial enrollment (range 3.1 to 11.6 months) in the six patients who have reached response assessment - - All six patients who have reached response assessment achieved a RANO objective response as their best overall response, with five patients showing complete responses (83.3%), including a previously reported stabl

      Nov 15Yahoo FinanceDRTS
      Alpha Tau Medical (DRTS) Stock May Be Hard To Justify Despite Its 343% Run
      Nov 7Yahoo FinanceDRTS
      Alpha Tau Signs MOU with Samsung Medical Center for Pancreatic Cancer Trial in Korea

      Detailed price information for Alpha Tau Medical Ltd Cl A (DRTS-Q) from The Globe and Mail including charting and trades.

      Oct 23The Globe and MailDRTS
      H.C. Wainwright reiterates Alpha Tau Medical stock rating on trial expansion
      Oct 21Investing.comDRTS
      How Investors Are Reacting To Alpha Tau Medical (DRTS) Expanded Brain Cancer Trial
      Oct 21Yahoo FinanceDRTS
      Alpha Tau Wins FDA Nod to Expand U.S. REGAIN Glioblastoma Trial, Data Heading to SNO 2026

      Detailed price information for Alpha Tau Medical Ltd Cl A (DRTS-Q) from The Globe and Mail including charting and trades.

      Oct 20The Globe and MailDRTS
      FDA Greenlights Expansion of Alpha Tau’s Brain Cancer Trial, With New Data Weeks Away (NASDAQ: DRTS) - Al

      WSW, NY, October 19th, 2026, FinanceWireFDA clearance doubles REGAIN’s permitted enrollment and broadens its clinical assessments, as Alpha Tau prepares to present updated results in November.Alpha Tau Medical

      Oct 19BenzingaDRTS
      FDA expands Alpha Tau glioblastoma trial to 20 patients
      Oct 19Investing.comDRTS
      Alpha Tau Medical Gets FDA Approval to Expand Brain Cancer Trial
      Oct 19Yahoo FinanceDRTS
      Alpha Tau to Participate in October Investor Conferences

      JERUSALEM, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that company management will participate in the following investor conferences in October 2026. Event:Fall Focus: Barclays Biotech 1x1 DayFormat:1x1 MeetingsDate:Tuesday, October 6, 2026Location:New York, NY Event:Investment Generation ConferenceFormat:PresentationDate:Thursday, Octob

      Oct 5Yahoo FinanceDRTS
      Alpha Tau Medical Ltd stock hits 52-week high at 15.2 USD
      Sep 16Investing.comDRTS
      Alpha Tau’s Cancer Trials Keep Beating Expectations. Three Major Data Readouts Are Next. By FinanceWire
      Sep 16Investing.comDRTS
      Alpha Tau's Cancer Trials Keep Beating Expectations. Three Major Data Readouts Are Next.
      Sep 15BenzingaDRTS
      Oramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More (ORMP)
      Sep 11Seeking AlphaDRTSLFWDORMPSCLX
      Alpha Tau Medical stock hits 52-week high at 15.11 USD
      Sep 4Investing.comDRTS
      Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough
      Sep 4Seeking AlphaDRTS
      Alpha Tau to Participate in September Investor Conferences

      JERUSALEM, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate in the following investor conferences in September 2026. Event:Citi's 2026 Biopharma Back to School ConferenceFormat:1x1 MeetingsDate:Wednesday, September 9, 2026Location:New York, NY Event:H.C. Wainwright 28th Annual Global Investor ConferenceFor

      Sep 2Yahoo FinanceDRTS
      H.C. Wainwright reiterates Alpha Tau Medical stock rating on trial enrollment
      Sep 1Investing.comDRTS
      Alpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions

      - IMPACT, a multicenter pilot study of Alpha DaRT® for newly diagnosed unresectable pancreatic cancer, expanded enrollment three times over the course of the study, from an original enrollment of 12 patients to a total of 48 treated patients, driven by overwhelming demand from patients and clinicians - - Alpha DaRT is delivered as a one-time add-on alongside standard first-line chemotherapy, an approach supported by the favorable safety profile observed in the earlier Israeli and Canadian studie

      Aug 31Yahoo FinanceDRTS
      Alpha Tau Medical stock hits 52-week high at 14.79 USD
      Aug 21Investing.comDRTS

      This is the newest page. Registered accounts read further back.